Rights and permissions
About this article
Cite this article
High cost of dalteparin not worth added benefits in cancer. Inpharma Wkly. 1488, 3 (2005). https://doi.org/10.2165/00128413-200514880-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200514880-00005